Future Planet, a global impact-led venture capital firm, led a $168m Series B funding round in Vaccitech, a clinical-stage biopharmaceutical company. Additional investors include M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund, and Oxford Sciences Innovation. “We expect this financing to enable us to reach key value inflection points for our lead programs. We now look forward to advancing key programs towards generating proof-of-concept data in indications with significant need of effective new treatments," Bill Enright, Vaccitech CEO.